NASDAQ:SKYE Skye Bioscience (SKYE) Stock Price, News & Analysis → The 2024 Gold Rush: Unleashing Market Potential (From Priority Gold) (Ad) Free SKYE Stock Alerts $12.15 +0.74 (+6.49%) (As of 05/14/2024 09:01 PM ET) Add Compare Share Share Today's Range$11.24▼$12.8650-Day Range$9.17▼$17.3652-Week Range$1.44▼$19.41Volume149,200 shsAverage Volume36,883 shsMarket Capitalization$150.05 millionP/E RatioN/ADividend YieldN/APrice Target$22.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial Media Get Skye Bioscience alerts: Email Address Skye Bioscience MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside85.2% Upside$22.50 Price TargetShort InterestHealthy0.29% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.24Based on 10 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.79) to ($0.88) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.14 out of 5 starsMedical Sector789th out of 928 stocksPharmaceutical Preparations Industry372nd out of 431 stocks 3.5 Analyst's Opinion Consensus RatingSkye Bioscience has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSkye Bioscience has only been the subject of 2 research reports in the past 90 days.Read more about Skye Bioscience's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.29% of the outstanding shares of Skye Bioscience have been sold short.Short Interest Ratio / Days to CoverSkye Bioscience has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Skye Bioscience has recently increased by 5.23%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSkye Bioscience does not currently pay a dividend.Dividend GrowthSkye Bioscience does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SKYE. Previous Next 1.5 News and Social Media Coverage News SentimentSkye Bioscience has a news sentiment score of -0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Skye Bioscience this week, compared to 1 article on an average week.MarketBeat Follows1 people have added Skye Bioscience to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Skye Bioscience insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.73% of the stock of Skye Bioscience is held by insiders.Percentage Held by InstitutionsOnly 21.09% of the stock of Skye Bioscience is held by institutions.Read more about Skye Bioscience's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Skye Bioscience are expected to decrease in the coming year, from ($0.79) to ($0.88) per share.Read more about Skye Bioscience's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stocks NewsWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarRevolutionizing communication is what this NASDAQ-traded next-gen solution provider is doing. See how this company is well-positioned to capitalize in 2024 About Skye Bioscience Stock (NASDAQ:SKYE)Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.Read More SKYE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SKYE Stock News HeadlinesMay 12 at 7:40 PM | nasdaq.comSkye Bioscience, Inc. Common Stock (SKYE) Dividend HistoryMay 12 at 7:40 PM | finance.yahoo.comSkye Bioscience, Inc.'s (NASDAQ:SKYE) last week's 13% decline must have disappointed private equity firms who have a significant stakeMay 10, 2024 | globenewswire.comSkye Bioscience Highlights Novel Synthetic Cannabinoid-based Library Capable of Modulating the Endocannabinoid System to Treat Ocular Diseases at ARVO 2024 Annual MeetingMay 10, 2024 | americanbankingnews.comContrasting Skye Bioscience (SKYE) and Its RivalsMay 9, 2024 | americanbankingnews.comSkye Bioscience (NASDAQ:SKYE) Trading Down 1.8%May 9, 2024 | americanbankingnews.comSkye Bioscience (NASDAQ:SKYE) Shares Down 1.8% April 30, 2024 | globenewswire.comSkye Bioscience to Present Two Posters at Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual MeetingApril 23, 2024 | globenewswire.comSkye Bioscience to Present at Upcoming Investment ConferencesApril 19, 2024 | investorplace.comThese 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher?April 18, 2024 | morningstar.comSkye Bioscience Inc Ordinary SharesApril 16, 2024 | investorplace.comThese 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?April 10, 2024 | finanznachrichten.deSkye Bioscience, Inc.: Skye Bioscience Uplists to The Nasdaq Global MarketApril 10, 2024 | globenewswire.comSkye Bioscience Uplists to The Nasdaq Global MarketMarch 15, 2024 | msn.comMercedes Mone Drops Julia Hart, Willow Nightingale Gets Main Event Win On AEW DynamiteMarch 14, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Guardant Health (GH), Cue Health (HLTH) and Skye Bioscience (OtherSKYE)March 13, 2024 | finanznachrichten.deSkye Bioscience, Inc.: Skye Bioscience Announces $40 Million Private Placement Equity FinancingMarch 8, 2024 | investorplace.comAll Three of Our Analysts AgreeMarch 4, 2024 | globenewswire.comSkye Bioscience Appoints Dr. Annalisa Jenkins to Board of DirectorsFebruary 26, 2024 | globenewswire.comSkye Bioscience Completes Enrollment of Phase 2a Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular HypertensionFebruary 7, 2024 | finance.yahoo.comSkye Bioscience to Present at Oppenheimer Investor ConferenceFebruary 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for Skye Bioscience on Strong Drug Pipeline and Financial HealthJanuary 30, 2024 | msn.comSkye Bioscience Announces Private Placement DetailsJanuary 30, 2024 | msn.comSkye Bioscience Strikes Deal for $50M Capital BoostJanuary 29, 2024 | msn.comSkye Bioscience announces $50M private placementJanuary 29, 2024 | finance.yahoo.comSkye Bioscience Announces $50.25 Million Private Placement Equity FinancingSee More Headlines Receive SKYE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Skye Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/10/2024Today5/15/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SKYE CUSIPN/A CIK1516551 Webskyebioscience.com Phone858-410-0266FaxN/AEmployees11Year FoundedN/APrice Target and Rating Average Stock Price Target$22.50 High Stock Price Target$25.00 Low Stock Price Target$20.00 Potential Upside/Downside+85.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,650,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-377.74% Debt Debt-to-Equity RatioN/A Current Ratio0.84 Quick Ratio0.84 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.17) per share Price / Book-71.47Miscellaneous Outstanding Shares12,350,000Free Float12,259,000Market Cap$150.05 million OptionableN/A Beta1.74 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Punit S. Dhillon B.A. (Age 44)Executive Chairman, President, CEO & Secretary Comp: $720kDr. Christopher G. Twitty Ph.D. (Age 51)Chief Scientific Officer Mr. Tu Diep M.Sc. (Age 43)Chief Development Officer Key CompetitorsInterCureNASDAQ:INCRCervoMedNASDAQ:CRVORegulus TherapeuticsNASDAQ:RGLSI-MabNASDAQ:IMABSagimet BiosciencesNASDAQ:SGMTView All Competitors SKYE Stock Analysis - Frequently Asked Questions Should I buy or sell Skye Bioscience stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Skye Bioscience in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SKYE shares. View SKYE analyst ratings or view top-rated stocks. What is Skye Bioscience's stock price target for 2024? 2 Wall Street analysts have issued 12 month price objectives for Skye Bioscience's shares. Their SKYE share price targets range from $20.00 to $25.00. On average, they predict the company's share price to reach $22.50 in the next year. This suggests a possible upside of 85.2% from the stock's current price. View analysts price targets for SKYE or view top-rated stocks among Wall Street analysts. How have SKYE shares performed in 2024? Skye Bioscience's stock was trading at $2.72 on January 1st, 2024. Since then, SKYE stock has increased by 346.7% and is now trading at $12.15. View the best growth stocks for 2024 here. When is Skye Bioscience's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024. View our SKYE earnings forecast. How were Skye Bioscience's earnings last quarter? Skye Bioscience, Inc. (NASDAQ:SKYE) posted its quarterly earnings data on Friday, May, 10th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by $0.02. What ETFs hold Skye Bioscience's stock? ETFs with the largest weight of Skye Bioscience (NASDAQ:SKYE) stock in their portfolio include AdvisorShares Pure Cannabis ETF (YOLO) and Tema Cardiovascular and Metabolics ETF (HRTS). How do I buy shares of Skye Bioscience? Shares of SKYE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SKYE) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersCharles Payne Demystifies OptionsUnstoppable ProsperityThe A.I. story nobody is telling you (Read ASAP)TradeSmithBuy this small stock before coming AI Tidal WaveChaikin AnalyticsRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap Sniper Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Skye Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
